Elimination of teicoplanin by adsorption to the filter membrane during haemodiafiltration: screening experiments for linezolid, teicoplanin and vancomycin followed by in vitro haemodiafiltration models for teicoplanin

Anaesthesia and Intensive Care
Y ShiraishiH Inaba

Abstract

Pharmaceutical agents directed against methicillin-resistant Staphylococcus aureus can be eliminated during haemodiafiltration, not only by diffusion and ultrafiltration, but also by adsorption onto haemofilters. The latter may be affected by the binding of agents to serum albumin. The present study therefore investigated the affinity of anti-methicillin-resistant Staphylococcus aureus agents (teicoplanin, linezolid, vancomycin) for haemofilters and the pharmacokinetic properties of teicoplanin during haemodiafiltration. Linezolid, teicoplanin and vancomycin were first screened for their in vitro affinity for three different kinds of filter membranes: polysulfone, polyacrylonitrile and polymethylmethacrylate. Only teicoplanin showed significant filter-binding activity. An in vitro haemodiafiltration circulation model was then developed that incorporated a one-litre beaker containing Krebs-Ringer's bicarbonate solution with/without human albumin (0 or 3 g/dl) as an artificial plasma. Teicoplanin (initial concentration 50 µg/ml, representing the maximum plasma concentration (Cmax) resulting from a typical clinical dosage) was circulated throughout the beaker. Teicoplanin concentrations in the 'plasma' and ultrafiltrate were deter...Continue Reading

References

Dec 1, 1992·Artificial Organs·O InagakiY Fujita
Jul 1, 1992·Antimicrobial Agents and Chemotherapy·J M QualeR H Barth
May 19, 1995·Journal of Chromatography. B, Biomedical Applications·J Luksa, A Marusic
Jun 1, 1994·Clinical Pharmacokinetics·F BressolleM Galtier
Apr 1, 1994·Journal of Clinical Pharmacy and Therapeutics·C A OborneN Barber
Oct 6, 2000·Clinical Pharmacokinetics·A P Wilson
Nov 18, 2005·Biomedical Chromatography : BMC·Lauren M BoakCraig R Rayner
Jul 21, 2006·International Journal of Antimicrobial Agents·Qi TianJeff Lipman
Aug 23, 2007·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Ikuo Aoike
Dec 19, 2007·Antimicrobial Agents and Chemotherapy·Qi TianGordon Y S Choi
Mar 11, 2008·Molecular Medicine·Taka-Aki NakadaHiroyuki Hirasawa
Jun 3, 2009·Critical Care Medicine·Gordon ChoiJeffrey Lipman
Dec 15, 2010·Clinical Pharmacokinetics·Marta UlldemolinsJeffrey Lipman

❮ Previous
Next ❯

Citations

Jun 27, 2013·The Journal of Antimicrobial Chemotherapy·Marjorie BeumierFabio Silvio Taccone
Apr 6, 2013·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Hiromi YanagimotoToshio Oguchi
Sep 30, 2017·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Yoshihiko NakamuraHiroyasu Ishikura
Jul 9, 2016·Therapeutic Drug Monitoring·Marco SartoriClaudio Ronco
Jan 31, 2018·Hemodialysis International·Heather A NymanAlfred K Cheung
Oct 21, 2019·Journal of Artificial Organs : the Official Journal of the Japanese Society for Artificial Organs·Dariusz OnichimowskiMirosław Czuczwar
Apr 12, 2017·Clinical Kidney Journal·Nynke G L JagerErik L Penne
Oct 10, 2020·Journal of Artificial Organs : the Official Journal of the Japanese Society for Artificial Organs·Dariusz OnichimowskiMirosław Czuczwar
Nov 27, 2020·Journal of AOAC International·Patrícia Aleixa Do NascimentoHérida Regina Nunes Salgado

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.